{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Two-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution. In the event of censoring before two years, a Kaplan-Meier estimate of the survival probability will be used and a Kaplan-Meier survival curve will be estimated and presented as well. The study was terminated prior to analyses","groups":[{"description":"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nRADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks.\n\nGemcitabine Hydrochloride: Given IV\n\nDocetaxel: Given IV\n\nInternal Radiation Therapy: Undergo brachytherapy\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nExternal Beam Radiation Therapy: Undergo EBRT\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT)"}],"populationDescription":"Data pertaining to Recurrence-free Survival was not collected/aggregated and therefore not analyzed.","reportingStatus":"POSTED","timeFrame":"Date of entry to date of reappearance of disease, assessed at 2 years. The study was terminated prior to analyses","title":"Recurrence-free Survival","type":"PRIMARY"}